IGF-I fusion polypeptides and therapeutic uses thereof

US7396918B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• David Glass · Cambridge, US
• George D. Yancopoulos · Elmhurst, US
• Thomas Daly · New City, US
• Nicholas J. Papadopoulos · Lagrangeville, US

Key dates

• Filing date: Jan 6, 2006
• Grant date: Jul 8, 2008
• Expiry date: Mar 23, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.